Lefisyo

Levomethadone Hydrochloride, the active ingredient in Lefisyo, is an opioid analgesic presented as an oral formulation for oral use. It is employed to manage moderate to severe pain and to support treatment of opioid dependence in appropriate patients, and is marketed within the European Union.

GNH USA supplies Lefisyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory compliance.

Levomethadone Hydrochloride is used in the management of pain and opioid dependence, acting on the mu‑opioid receptor pathway.

- Moderate to severe pain: provides analgesia for acute or chronic pain conditions where strong opioid therapy is indicated. - Opioid dependence treatment: assists in detoxification and maintenance therapy for individuals with opioid use disorder. - Post‑surgical pain: helps control pain following major surgical procedures when other analgesics are insufficient.

Levomethadone Hydrochloride may cause a range of adverse reactions, from mild to severe, depending on individual sensitivity and dosage.

Common Side Effects: - Nausea or vomiting - Constipation - Drowsiness or sedation - Dizziness or light‑headedness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression, which can be life‑threatening - Severe hypotension or cardiac arrhythmias - Allergic reactions such as rash, itching, or anaphylaxis

When prescribing Lefisyo, clinicians should consider several safety measures to minimize risks.

- Assess patient history: evaluate prior opioid use, respiratory conditions, and hepatic or renal impairment. - Monitor for sedation: advise patients to avoid operating machinery or driving until they know how the drug affects them. - Avoid abrupt discontinuation: taper the dose gradually to prevent withdrawal symptoms. - Use caution in the elderly: start with the lowest effective dose and monitor closely for adverse effects. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Levomethadone Hydrochloride can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase levomethadone plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce drug concentrations, diminishing analgesic effect. - Serotonergic agents (e.g., SSRIs, tramadol) could increase the risk of serotonin syndrome. - Anticholinergic drugs may exacerbate constipation, requiring proactive bowel regimen.